Krebiozen & Cancer

''The stage is now set for ultimate resolution of this thing," said Director Kenneth Endicott of the National Cancer Institute last week, with a vast sigh of relief. Under last year's tightened drug-control laws, the Food and Drug Administration is at last launching an all-out investigation to answer a question that has caused savage controversy for twelve years: Is there any basis for the claims that Krebiozen, a mysterious horse-serum drug, is a cure for some forms of cancer? Though Krebiozen has never been approved by any federal agency, about 3,500 doctors have given it to about 5,000 patients. Last week FDA began gathering evidence to establish:

> Full details on the manufacture, strength, purity and safety of Krebiozen.

> Whether it can qualify for sale under an FDA license.

> Whether, before full licensing for sale, doctors may continue using it as an investigational drug--which means they must keep detailed scientific records on every patient treated.

Yugoslav-born Dr. Stevan Durovic, developer of the drug, and the laboratories which distribute it claim that it is not sold, but that doctors using it make a $9.50 "contribution" to the Krebiozen Research Foundation. The FDA charges flatly that "Krebiozen has been promoted and sold as a cancer remedy." If this is so, FDA now has power to stop its distribution. The Government can ban further use of Krebiozen unless its promoters can show, by June 7, that they are making a truly scientific investigation of it, or that it has shown enough evidence of curative powers to justify its continued use.

This file is automatically generated by a robot program, so reader's discretion is required.